Blogger

ViiV goes for gold: US premium pricing may threaten dolutegravir use in Europe

On 12 August 2013, the FDA approved dolutegravir in the US. i-Base reported the news with an article linked to previous clinical trial results that noted not only the potential advantages but also some of the cautions.  One of the concerns was how the price, which didn’t accompany the original company press statement, would be …

ViiV goes for gold: US premium pricing may threaten dolutegravir use in Europe Read More »

Monthly or Quarterly Injectable HIV Antiretrovirals Are Safe and Effective in Early Study

GSK744, an investigational integrase inhibitor, and TMC278 LA (a long-acting, injectable form of the NNRTI rilpivirine [Edurant]) both showed safety and efficacy when administered in once-monthly or once-quarterly doses, according to a study presented at IAS 2013. There were no drug-related serious adverse events and all adverse events were either mild or moderate. The phase 1 …

Monthly or Quarterly Injectable HIV Antiretrovirals Are Safe and Effective in Early Study Read More »

The Future of HIV Treatment is Here: Once-a-Month Injections to Replace Daily Oral Medications

A combination of antiretroviral drugs in long-acting nanosuspension formulations achieved adequate blood levels and appeared safe in HIV negative study volunteers, offering the potential for a maintenance or PrEP option that could be taken once monthly, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur. While modern antiretroviral therapy is highly safe and …

The Future of HIV Treatment is Here: Once-a-Month Injections to Replace Daily Oral Medications Read More »

Calimmune Initiates HIV Stem Cell Study at Two California Research Sites

(Los Angeles, CA) — The HIV gene medicines company Calimmune announced today that the first patient has begun treatment in a Phase I/II clinical trial designed to determine whether a pioneering genetic medicine approach can help to protect individuals infected with HIV from the effects of the virus. The study, “Safety Study of a Dual …

Calimmune Initiates HIV Stem Cell Study at Two California Research Sites Read More »

Two More Patients Are Cured of HIV- And This Time With A Less Complex Regimen

“Both the surviving patients had been receiving prolonged antiretroviral therapy and received stem cell transplants with a reduced-intensity conditioning regimen of chemotherapy designed to eradicate the cancer and eliminate the existing bone marrow. In the case of the two patients under investigation, the conditioning regimen did not include radiotherapy and it did not eliminate the …

Two More Patients Are Cured of HIV- And This Time With A Less Complex Regimen Read More »

New HIV Eradication Study: The Use of a Personalized ImmuneTherapy (AGS-004) with a Reservoir Activating Agent

Argos Therapeutics Announces Plans for HIV Eradication Study  “To create AGS-004, ribonucleic acid (RNA) is isolated from HIV particles obtained from patients, and dendritic cells are generated from a single leukapheresis procedure. Selected RNAs are then used to “program” the dendritic cells with the patient-specific payload to trigger an immune response against the patient’s HIV …

New HIV Eradication Study: The Use of a Personalized ImmuneTherapy (AGS-004) with a Reservoir Activating Agent Read More »

Free 2013 Report: New HIV, HCV and TB Drugs, Diagnostics, and Vaccines in the Research Pipeline

HIV i-Base/Treatment Action Group 2013 Pipeline Reportcalls on leaders to get the best HIV, hepatitis C virus (HCV), and tuberculosis drugs, diagnostics, and vaccines to the most people as quickly as possible– Survey shows HIV pipeline healthy, HCV drug development surging,while TB research moves forward much too slowly – – Faster research, approval, and access demanded …

Free 2013 Report: New HIV, HCV and TB Drugs, Diagnostics, and Vaccines in the Research Pipeline Read More »

ResearchMatch Connects HIV Study Volunteers with Researchers

I highly encourage everyone to join our important attempt to accelerate the cure of HIV.  Research Match also helps connect patients with other diseases with private investigators. Please forward to your friends and families.  Anyone can participate. Thank you in advance for supporting this platform! Contact: Kathy Edson (615) 343-2571/ kathleen.edson@vanderbilt.edu ResearchMatch Connects HIV Study Volunteers with Researchers Nashville, TN – June 1, 2013 — ResearchMatch (RM), the country’s first nationwide, non-profit research volunteer recruitment platform for all …

ResearchMatch Connects HIV Study Volunteers with Researchers Read More »

SANGAMO BIOSCIENCES PRESENTS CLINICAL DATA DEMONSTRATING HIV RESERVOIR REDUCTION IN HIV-INFECTED SUBJECTS TREATED WITH MODIFIED IMMUNE CELLS WITH ZINC FINGER NUCLEASES

SANGAMO BIOSCIENCES PRESENTS CLINICAL DATA DEMONSTRATING HIV RESERVOIR REDUCTION IN HIV-INFECTED SUBJECTS TREATED WITH ZFP THERAPEUTIC®, SB-728-T Unprecedented Immune Reconstitution Drives HIV Viral Reservoir DepletionEncouraging Preliminary Anti-Viral HIV Data during Treatment Interruption in Ongoing SB-728-T Phase 2 Trials Richmond, California, May 15, 2013 – Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of new …

SANGAMO BIOSCIENCES PRESENTS CLINICAL DATA DEMONSTRATING HIV RESERVOIR REDUCTION IN HIV-INFECTED SUBJECTS TREATED WITH MODIFIED IMMUNE CELLS WITH ZINC FINGER NUCLEASES Read More »

Report from CROI-2013- My Personal Picks

CROI 2013 Report Nelson Vergel I was happy to attend  CROI-2013 in Atlanta on March 3-6, 2013.  These are areas of great interest to me and in no way attempts to summarize the main findings reported at the conference.  For abstract information, refer to https://www.retroconference.org/AbstractSearch/default2.aspx?conf=22 A baby girl gets cured   The most popular media …

Report from CROI-2013- My Personal Picks Read More »